Medicare Advantage Plan Beneficiaries Receiving the COVID-19 Vaccine and Monoclonal Antibody
Effective 1/1/2022, claims for COVID-19 vaccinations or monoclonal antibody treatment provided to patients enrolled in MA plans on or after 1/1/ 2022, must be submitted to the patient’s MA Plan.
Original Medicare will no longer make payment for these services provided to a MA Plan patient. Questions about Original Medicare nonpayment for these services as of 1/1/2022, direction on billing the MA Plan or MA Plan payment amounts must be directed to the individual patient’s MA Plan.
COVID-19 vaccines and monoclonal antibody treatments provided to MA plan patients prior to 1/1/2022, continue to be billed to Original Medicare.
Related Content:
Posted 3/1/2022